(Q43282351)

18 November 2017

title

Discontinuation of enfuvirtide in heavily pretreated HIV-infected individuals (English)

1 reference

18 November 2017

Matthias Cavassini

5

0 references

Manuel Battegay

9

object named as

Manuel Battegay

1 reference

18 November 2017

Swiss HIV Cohort Study

10

object named as

Swiss HIV Cohort Study

1 reference

18 November 2017

8

Enos Bernasconi

1 reference

18 November 2017

6

Bernard Hirschel

1 reference

18 November 2017

Luigia Elzi

1

1 reference

18 November 2017

Gilbert Kaufmann

2

1 reference

18 November 2017

Rainer Weber

3

1 reference

18 November 2017

Christoph A Fux

4

1 reference

18 November 2017

Pietro Vernazza

7

1 reference

18 November 2017

publication date

1 July 2009

1 reference

18 November 2017

1 reference

18 November 2017

volume

10

1 reference

18 November 2017

issue

4

1 reference

18 November 2017

page(s)

207-214

1 reference

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

18 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1310%2FHCT1004-207

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1004-207

Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1004-207

TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1004-207

Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1004-207

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug r

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1004-207

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1004-207

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1004-207

Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1004-207

Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1004-207

Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1004-207

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1004-207

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1004-207

Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1004-207

Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1004-207

21 January 2018

Identifiers

DOI

10.1310/HCT1004-207

1 reference

release_v3lria64znhqzdzkcmbqt3k6ku

18 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/v3lria64znhqzdzkcmbqt3k6ku

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference